- Home
- GTLS vs QGEN Comparison
GTLS vs QGEN Comparison
Compare GTLS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTLS | QGEN |
|---|---|---|
| Founded | 1859 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.2B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | GTLS | QGEN |
|---|---|---|
| Price | $207.97 | $37.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $202.63 | $50.26 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 6.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.31 | $8.18 |
| Revenue Next Year | $5.89 | $5.71 |
| P/E Ratio | $240.25 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $127.40 | $38.80 |
| 52 Week High | $208.51 | $57.82 |
Technical Indicators
Market Signals| Indicator | GTLS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 29.09 |
| Support Level | $206.51 | N/A |
| Resistance Level | $208.38 | $48.53 |
| Average True Range (ATR) | 0.42 | 0.86 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 65.41 | 8.52 |
Price Performance
Historical ComparisonAbout GTLS Chart Industries Inc.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).